Methysergide in the migraine syndrome

Publisher Website
Google Scholar
Abstract
Methysergide and a placebo were compared under double‐blind conditions for prophylactic effect in patients exhibiting the migraine syndrome. Each patient received in randomized order 2 mg. methysergide, three times a day orally for 5 consecutive weeks, and an identical placebo taken in the same way during another period of 5 weeks. The number of headache days reported by each patient during the last 4 weeks of the methysergide period was subtracted from the number reported during the last 4 weeks of the placebo period. These observations were analyzed sequentially with Rushton's t test. After 13 patients had completed both treatment periods, the data were sufficient to conclude that methysergide was significantly (P < .05) more helpful than the placebo in reducing the frequency of migraine headache attacks. No serious toxic effects of methysergide were noted.

This publication has 0 references indexed in Scilit: